China Apis CAS 866460-33-5 Setipiprant Powder 99% Setipiprant Powder, Find details about China Setipiprant, Setipiprant Powder from Apis CAS 866460-33-5 Setipiprant Powder 99% Setipiprant Powder
APIs CAS 866460-33-5 Setipiprant Powder 99% Setipiprant Powder | |
Item Name | Setipiprant |
CAS NO. | 866460-33-5 |
Apparence | White Powder |
package | Aluminum Bag;Drums |
Purity | 99% |
Advantage | OEM;ODM |
Warranty | 2 Years If Keep It Well |
Certificate | GMP/ISO9001 |
Payment | Trade Assurance;L/C;T/T;Western Union |
Setipiprant (INN) (developmental code names ACT-129,968, KYTH-105) is a drug originally developed by Actelion which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.
However, following the discovery in 2012 that the prostaglandin D2 receptor (DP/PGD2) is expressed at high levels in the scalp of men affected by male pattern baldness, the rights to setipiprant were acquired by Kythera with a view to potentially developing this drug as a novel treatment for baldness, with a previously unexploited mechanism of action. While it is too early to tell whether setipiprant will be an effective treatment for this condition, the favorable pharmacokinetics and relative lack of side effects seen in earlier clinical trials mean that fresh clinical trials for this new application can be conducted fairly quickly.
A phase 2A study is underway to evaluate the safety, tolerability, and efficacy of oral setipiprant relative to a placebo and the active comparator, finasteride, in 18 to 41 years old males with androgenetic alopecia.
Setipiprant is the drug for the treatment of hair loss dwindled, perhaps due more to commercial potential and chemical stability reasons than efficacy as the later studies of Setipiprant have focused on different chemical forms of the drug and combining it with various nanoparticles to enhance delivery
1.Setipiprant as pharmaceutical raw materials.
2.Setipiprant for the prevention of hair loss.
3.Setipiprant solution for hair loss.
4.Setipiprant can reduce the hair loss caused by chemotherapy.
5.Setipiprant treatment of alopecia areata has a certain effect.
6.Setipiprant is a vasodilator for the treatment of hypertension.
7.Setipiprantcan treat seborrheic alopecia, male hair loss, or early morning baldness.
Items | Standards | Results |
Physical Analysis | ||
Description | White Powder | Complies |
Assay | 99% | 99.6% |
Mesh Size | 100 % pass 80 mesh | Complies |
Ash | ≤ 5.0% | 2.85% |
Loss on Drying | ≤ 5.0% | 2.85% |
Chemical Analysis | ||
Heavy Metal | ≤ 10.0 mg/kg | Complies |
Pb | ≤ 2.0 mg/kg | Complies |
As | ≤ 1.0 mg/kg | Complies |
Hg | ≤ 0.1 mg/kg | Complies |
Microbiological Analysis | ||
Residue of Pesticide | Negative | Negative |
Total Plate Count | ≤ 1000cfu/g | Complies |
Yeast&Mold | ≤ 100cfu/g | Complies |
E.coil | Negative | Negative |
Salmonella | Negative | Negative |